Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | Y005835 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | W007025 | — |
The patient did not report any adverse issues or side effects from any of the administered doses; A patient who is currently 13 years old received their first dose on 06/19/2023 (lot: W007025 expiration: unknown) and a second dose today, 04/15/2025 (lot: Y005835 e; This spontaneous report was received from a nurse referring to a 13-year-old female patient. Information regarding the patient's concurrent conditions, medical history, or concomitant medications was not provided. On 19-JUN-2023, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) injection, for prophylaxis (dose, route of administration, strength and anatomical location were not provided; valid lot number W007025, with expiration date not provided but upon internal validations established as 04-DEC-2024). On 15-APR-2025, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine (GARDASIL 9) injection as a dose of 0.5 ml, for prophylaxis (route of administration, strength and anatomical location were not provided; valid lot number Y005835, with expiration date on 06-JUN-2026). (Inappropriate schedule of product administration). There was no adverse effect reported.